In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women

Am J Obstet Gynecol. 2012 Jul;207(1):65.e1-10. doi: 10.1016/j.ajog.2012.04.029. Epub 2012 Apr 30.

Abstract

Objective: To evaluate whether cervicovaginal secretions inhibit HIV-1 infectivity in an in vitro model, and estimate concentration of immune mediators.

Study design: We enrolled midtrimester pregnant and regularly menstruating (nonpregnant) women. Cervicovaginal lavage was collected at 2 visits and incubated with HIV-1 and TZM-bl cells. Infectivity was compared with positive controls. Concentrations of immune mediators were compared between groups.

Results: At enrollment, cervicovaginal lavage inhibited IIIB virus 88.2% and 82.4%, and BaL virus 72.8% and 77.9%, among pregnant (n = 13) and nonpregnant women (n = 9), respectively. At second visit, cervicovaginal lavage inhibited IIIB 89.7% and 82.5%, and BaL 77.4% and 69.9% among pregnant (n = 15) and nonpregnant women (n = 8), respectively (all P ≤ .04). Adjusting for body mass index, race, and protein content of cervicovaginal lavage, antimicrobials were suppressed but cytokines and chemokines were not markedly different in pregnancy.

Conclusion: Cervicovaginal secretions significantly suppress HIV-1 infectivity in this model. Concentrations of certain immune mediators are altered in pregnancy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / metabolism
  • Cervix Uteri / immunology*
  • Cervix Uteri / metabolism
  • Cervix Uteri / virology
  • Chemokines / metabolism
  • Cytokines / metabolism
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • Humans
  • Immunity, Mucosal
  • In Vitro Techniques
  • Pregnancy / immunology*
  • Vagina / immunology*
  • Vagina / metabolism
  • Vagina / virology
  • Vaginal Douching
  • Young Adult

Substances

  • Biomarkers
  • Chemokines
  • Cytokines